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Background: Concentrations of C-reactive protein (CRP), interleukin 6 (IL-6) and other 
inflammatory markers are elevated in people with depression and anxiety compared to 
controls, but evidence for disorder-specificity, linearity and potential causality is sparse. 
Methods: Using population-based data from up to 144,890 UK Biobank cohort participants, 
we tested associations of circulating CRP concentrations with depression and anxiety 
symptom scores and probable diagnosis, including tests for linearity, disorder-specificity and 
sex difference. We examined potential causality using 1-sample and 2-sample Mendelian 
randomisation (MR) analyses testing associations of genetically-predicted CRP concentration 
and IL-6 activity with depression and anxiety. The study was conducted from June 2019 to 
February 2021. 
Findings: CRP concentration was associated with depressive and anxiety symptom scores 
and with probable diagnoses of depression and generalised anxiety disorder (GAD) in a dose-
response fashion. These associations were stronger for depression than for anxiety, and for 
women than for men although less consistently. MR analyses provided consistent results 
suggesting that genetically predicted higher IL-6 activity was associated with increased risk 
for depressive symptoms, while genetically-predicted higher CRP concentration was 
associated with decreased risks of depressive and anxiety symptoms. 
Interpretation: Altered activity of the IL-6/IL-6R pathway could be a risk factor for 
depression. The field now requires experimental studies of IL-6 modulation in humans and 
animal models to further examine causality, mechanisms and treatment potential. Such 
studies are also needed to elucidate mechanisms for divergent associations of genetically-
predicted higher IL-6 activity (risk increasing) and higher CRP concentrations (protective) 
with depression/anxiety. 
Funding: MQ (MQDS17/40); Wellcome Trust (201486/Z/16/Z). 




RESEARCH IN CONTEXT 
Evidence before this study 
Systematic reviews and meta-analyses suggest concentrations of circulating CRP and other 
inflammatory markers are elevated in patients with depression and generalised anxiety 
disorder as compared to healthy controls. However, there are key outstanding questions: (1) 
Is inflammation a potentially causal factor for depression and anxiety disorders; (2) is 
inflammation a specific or common risk factor for depression and anxiety, which are highly 
comorbid; (3) is there a sex difference in the associations between inflammation and risks for 
affective symptoms/disorders, and are these associations linear or quadratic? 
Added value of this study 
We report that inflammation is associated with depression and anxiety in a linear dose-
response fashion, and more strongly in women than in men, albeit less consistently. The 
associations were larger for depression than for anxiety and persist after controlling for 
current anxiety symptoms, but not vice versa, indicating disorder specificity. Furthermore, 
using Mendelian randomization analysis we report that genetically-predicted higher IL-6 
activity and genetically-predicted lower CRP concentrations are associated with increased 
risk of depressive symptoms, suggesting that inflammation, particularly altered activity of the 
IL-6/IL-6R pathway, could be a risk factor for depression. 
Implications of all the available evidence 
Evidence for a role of IL-6 in depression supports the need for experimental studies in 
humans and animals to further investigate causality, mechanisms and treatment potential. 
Evidence that inflammation could represent a relatively larger risk factor for depression than 
for anxiety could inform patient selection criteria in immunotherapy trials. Experimental 
studies are also required to elucidate mechanisms for divergent effects for CRP and IL-6 on 





Innate immune dysfunction represents a putative mechanism for depression and other 
psychiatric disorders opening up the possibility of new treatment approaches distinct from 
current monoaminergic drugs.1,2 In depression, for instance, there is evidence of low-grade 
systemic inflammation as indexed by elevated concentrations of C-reactive protein 
(CRP >3mg/L) in 21–34% of patients,3 along with increased concentrations of interleukin-6 
(IL-6) and other inflammatory cytokines in blood and in cerebrospinal fluid (CSF).4–8 A 
number of randomised controlled trials (RCTs) are now testing the effects of anti-
inflammatory drugs in patients with depression (e.g., Khandaker et al.9, NCT02473289, 
NCT02362529). However, there are key outstanding questions, particularly regarding 
specificity and causality of association, that require addressing for a clearer understanding of 
the potential role of inflammation in illness pathogenesis and to inform future clinical trials.  
Depressive disorders overlap with anxiety disorders both genetically and clinically.10,11 
Anxiety symptoms now form part of the diagnostic criteria for major depressive disorder 
(MDD) as “anxious distress specifier” in the diagnostic and statistical manual of mental 
disorders 5th edition (DSM-5).12 Preliminary evidence from case-control studies also indicates 
that inflammation could be implicated in generalized anxiety disorder (GAD), although 
findings from studies are mixed and prospective studies indicate that inflammation could 
increase subsequent to the development of an anxiety disorder.13,14 Additionally, to our 
knowledge no studies have tested whether inflammation is a common or specific risk factor 
for depression and anxiety. This is an important issue as it may help to identify potentially 
unique or shared mechanisms for psychiatric disorders that commonly co-occur. 
Regarding causality, longitudinal studies and meta-analyses have reported evidence for a 
temporal association between elevated CRP and IL-6 concentrations at baseline and risk of 
depressive symptoms subsequently,15–18 but other studies have not fully replicated 
associations of these markers with subsequent depressive disorders19,20 and residual 
confounding still remains a possibility. Mendelian randomization (MR) is an epidemiological 
approach that uses genetic variants as instruments to untangle the problem of unmeasured 
confounding as genetic variants are randomly inherited from parents to offspring and fixed at 
conception.21 Therefore, if genetically-predicted values of a risk factor are associated with a 
disease outcome, then it is likely the association between the risk factor and outcome has a 




Existing MR studies have provided mixed evidence on the association of inflammation with 
different psychiatric disorders. Hartwig et al. reported potential protective effects of elevated 
CRP for schizophrenia,22 contrasting with findings from observational studies.23,24 For 
depression, one study did not find evidence for a potential causal role of inflammation,25 
while more recent studies reported potential causal roles for increased IL-6 and CRP serum 
concentrations in depression,26 for increased IL-6 activity for suicidality specifically,27 and 
for increased soluble IL-6R levels for recurrent depressive symptoms.28 While these findings 
may indicate disorder-specificity, further research is required to enable definite conclusions 
regarding causality of association. Furthermore, to our knowledge, MR studies of 
inflammation and anxiety have thus far only investigated individual anxiety symptoms.29 
We have used data from up to 144,890 individuals from the UK Biobank study, a large 
general population-based cohort, to test associations of circulating CRP concentrations with 
depression and anxiety. As outcomes, we have used symptom scores and categorical probable 
diagnosis in the total sample and in men and women separately to assess potential sex 
difference, strength and reproducibility of association. We have examined evidence for dose-
response by testing linearity of association. We have examined specificity of association by 
testing whether the association of CRP with depression and anxiety is stronger for one 
outcome than the other, or is similar between outcomes. Furthermore, we have carried out 
MR analysis in the full sample, and in men and women separately, to test whether 
associations of CRP and IL-6 with depression and anxiety are consistent with potential causal 






The UK Biobank is a population-based cohort with a range of phenotyping assessments, 
biochemical assays and genome-wide genotyping from over 500,000 UK residents aged 40-
69 years at baseline, recruited between 2006 and 2010 from 22 assessment centres throughout 
the UK.30 Our primary outcomes were depressive and anxiety symptoms that were assessed 
online as part of a follow-up mental health survey completed by up to 157,115 individuals 
between July 2016 and July 2017.31 The current study used available data from the maximum 
number of UK Biobank participants for each analysis (N up to 144,890). The UK Biobank 
study was subject to ethics committee approval and participants gave their informed consent 
prior to participation; see details in Supplementary Methods. 
 
Exposure 
Using blood samples collected in the UK Biobank baseline visit between 2006 and 2010 or 
the first repeat assessment visit between 2012 and 2013, serum high-sensitivity CRP 
concentrations were measured by immunoturbidimetric assay on a Beckman Coulter 
AU5800. Minimum detection limit was 0·08 mg/L. CRP values in the entire sample 
(n=486,424) ranged from 0·08 to 79·96 mg/L; mean=2·60 (SD=4·36) mg/L. The distribution 
of CRP concentrations for this study (n=146,954) was divided into quintiles or deciles, which 
were used as categorical variables. We also carried out additional analyses using CRP as a 
continuous variable (natural log-transformed).  
 
Outcomes 
Our primary outcomes were depressive and anxiety symptoms occurring in the last 2 weeks 
as measured using the Patient Health Questionnaire (PHQ)-9 and the Generalised Anxiety 
Disorder (GAD)-7 questionnaire, respectively.32,33 Symptoms were coded as 0-3 depending 
on self-reported severity. We created sum-scores for each scale, which were used as primary 
outcomes. Categorical diagnoses of probable depression and GAD were used as secondary 
outcomes, which were defined using commonly used cut-off criteria of PHQ-9≥10 and GAD-






As covariates, we included age, sex, body mass index (BMI), smoking, alcohol use, physical 
activity, ethnicity, Townsend Deprivation Index (TDI), and diabetes and cardiovascular 
disease; see Supplementary Appendix for details.  
 
Statistical Analyses 
Analyses were performed using Stata/SE 16.0 (Stata, College Station, TX). Baseline 
characteristics of participants were examined across CRP quintiles.  
Association of CRP with depression and anxiety, linearity and sex difference 
Linear regression was used to estimate the associations between CRP concentrations 
(quintiles or deciles) and depressive and anxiety symptom scores. For the purpose of 
interpretation, coefficient estimates were anti-log transformed to odds ratio and 95% 
confidence interval (CI). We adjusted regression models for age, sex, BMI, smoking, alcohol 
use, physical activity, ethnicity, TDI, and diabetes and cardiovascular disease.  
To investigate the nature of associations with depressive and anxiety symptoms and any 
dose-response effect in greater detail, CRP concentrations were divided into deciles with 
deciles 2-10 compared with the lowest decile group (decile 1). Floating absolute risks were 
estimated, which were then plotted against the median CRP concentrations in each decile. We 
computed ORs for trend by using quintile number as predictor. We assessed potential 
quadratic associations by including a quadratic term (CRP-squared). We performed sex-
stratified analyses and also tested for interaction between sex and CRP by including 
interaction terms in regression models. Lastly, we evaluated the influence of 
selection/collider bias for participation in the optional mental health survey using inverse 
probability weighted regression of the fully adjusted regression models of depression and 
anxiety outcomes on CRP;34,35 see Supplementary Methods for details. 
Test for specificity vs commonality of association of CRP between depression and anxiety 
We used bivariate probit regression to test for specificity of association of CRP between 




jointly modelled the outcomes of depression and anxiety with CRP, and then tested for 
equality of regression parameters expressing the effect of CRP on each outcome using the 
likelihood ratio test. We compared a model that allowed estimates to differ between outcomes 
with a model where estimates were constrained to be equal for both outcomes. Probit 
estimates were converted into ORs by multiplying probit parameters by 1·6.36 In addition, we 
adjusted the regression models of depression for anxiety (along with other covariates) and 
vice versa as additional tests for disorder specificity. 
 
Mendelian randomisation approach 
Genotyping  
We used genotyping data of 342,081 unrelated individuals of White ancestry; see 
Supplementary Methods for details on genotyping array, central and post-imputation quality 
control. We used a summary-based approach for MR analyses,37 so sample sizes differed for 
estimation of SNP-exposure and SNP-outcome associations. For estimation of SNP-outcome 
associations, sample sizes varied between 100,739-110,173 per outcome; see Supplementary 
Table 1 for sample sizes for SNP-exposure associations. 
SNP selection 
We selected genetic variants in the CRP and IL-6 receptor (IL6R) gene regions previously 
shown to be associated with CRP or IL-6 concentrations (Supplementary Table 1).38–41 
Genetic instruments differ in strength based on the precision with which they have been 
estimated in original GWAS studies. As instrument strength informs statistical power for MR 
analysis, we used genetic instruments from Georgakis et al.38 for primary MR analysis, which 
have the largest strength (Supplementary Table 1), and report results from other 
instruments39–41 as sensitivity analysis.  
We extracted SNP-exposure estimates from previous reports to perform 2-sample MR 
analysis. Based on availability of CRP concentrations in the UK Biobank study, which can be 
used as downstream readout of IL-6 activity under the classic IL-6 signalling pathway,38 we 
also estimated SNP-exposure associations (for 1-sample MR) and SNP-outcome associations, 
in the full sample and separately for men and women for sex-stratified MR; see details in 




Mendelian randomisation analyses 
We performed MR analysis using inverse-variance weighted (IVW) regression of the genetic 
associations with the outcome on the genetic associations with the exposure.37 To evaluate 
the potential impact of selection/collider bias for participation in the optional mental health 
survey, we repeated IVW MR analyses with SNP-outcome associations obtained using 
inverse probability weighted regression.34 We also evaluated potential horizontal pleiotropy 
using Cochran’s Q.37 See details in Supplementary Appendix.  
 
Role of the funding source 
The funding sources had no role in study design; collection, analysis, and interpretation of 







In 146,954 participants (43·6% men), mean age at recruitment was 56·5 (SD=7·8) years. 
Median CRP concentration was 1·15 mg/L (IQR=0·58-2·38 mg/L). Table 1 shows 
characteristics of study participants by CRP quintiles. Mean depressive symptom scores were 
2·76 (SD=3·70, range: 0-27) and mean anxiety symptom scores 2·15 (SD=3·41, range: 0-21); 
these scores exhibited a moderate-to-large correlation (Pearson’s r=0·68). 5·5% of 
individuals qualified for a probable diagnosis of depression, 4·4% for a probable diagnosis of 
GAD, and 0·6% for both probable depression and probable GAD. 
  
Association of CRP Concentration with Depressive and Anxiety Symptom Scores 
Results for associations of CRP with depressive and anxiety symptoms are presented in 
Figure 1 across different CRP deciles in the total sample, and for women and men separately 
in Supplementary Figures 2 and 3. Overall, CRP was associated with depressive and anxiety 
symptoms after adjusting for all potential confound factors, but adjustment for BMI 
attenuated these associations to some extent (Supplementary Tables 2 & 3). 
Using CRP as a continuous variable, the adjusted OR for higher depressive symptom score 
per-unit increase in log CRP was 1·09 (95% CI, 1·06-1·11). Using CRP as a categorical 
variable, the adjusted OR for higher depressive symptom score for participants in the top, 
compared with bottom, quintile of CRP was 1·29 (95% CI, 1·21-1·38). Inverse probability 
weighted regression analyses of depressive symptoms did not suggest that results were 
affected by collider bias, as the adjusted OR=1·31 (95% CI, 1·22-1·41) for participants in the 
top, compared with bottom, quintile of CRP was similar. 
Using CRP as a continuous variable, the adjusted OR for higher anxiety symptom score per-
unit increase in log CRP was 1·03 (95% CI, 1·02-1·05). Using CRP as a categorical variable, 
the adjusted OR for higher anxiety symptom score for participants in the top, compared with 
bottom, quintile of CRP was 1·12 (95% CI, 1·05-1·19). Again, evidence did not suggest 






Association of CRP Concentration with Probable Diagnoses of Depression and GAD 
CRP was associated with probable diagnosis of depression (Table 2). Using CRP as a 
continuous variable, the adjusted OR for depression per-unit increase in log CRP was 1·09 
(95% CI, 1·06-1·11). Using CRP as a categorical variable, the adjusted OR for depression for 
participants in the top, compared with bottom, quintile of CRP was 1·29 (95% CI, 1·18-
1·40). Evidence did not suggest results were affected by collider bias with similar OR of 1·29 
(95% CI, 1·18-1·41) in sensitivity analyses. 
 
CRP was associated with probable diagnosis of GAD (Table 3). Using CRP as a continuous 
variable, the adjusted OR for GAD per-unit increase in log CRP was 1·05 (95% CI, 1·02-
1·08). Using CRP as a categorical variable, the adjusted OR for GAD for participants in the 
top, compared with bottom, quintile of CRP was 1·15 (95% CI, 1·05-1·26). Again, evidence 
did not support collider bias as likely explanation with similar OR of 1·13 (95% CI, 1·02-
1·24) in sensitivity analyses. 
 
 
Test for specificity vs commonality of association of CRP with depression and anxiety  
In bi-variate probit regression analysis, we found evidence for a stronger association of CRP 
with depressive symptoms (OR=1·014; 95% CI, 1·011-1·017) than anxiety symptoms 
(OR=1·004; 95% CI, 1·002-1·007). Results for probit regression using probable diagnoses of 
depression and GAD as outcomes were similar (see Supplementary Results).  
In regression analyses, evidence for association of CRP with depression symptoms remained 
after adjusting for anxiety symptoms (OR=1·06; 95% CI, 1·05-1·08), but the association of 
CRP with anxiety symptoms switched its valence after adjusting for depressive symptoms 





Linearity of association 
Evidence was compatible with linear associations of CRP with both depression and anxiety 
across all analyses using symptom scores and probable diagnoses as outcomes (P-value for 
all quadratic terms >0·05). 
 
Examination of potential sex difference 
In sex-stratified analyses, point estimates were larger for women than men for both 
depression and anxiety symptom outcomes (Supplementary Tables 2-3, Supplementary 
Figures 2-3). However, evidence for an interaction between CRP and sex was present only 
for depressive symptoms (adjusted ORwomen=1·35; 95%CI, 1·23-1·48; adjusted ORmen=1·21; 
95%CI, 1·10-1·33; P-value for interaction term=0·032). For categorical outcomes, point 
estimates were larger for women for probable GAD (Tables 2-3), but evidence did not 
support interaction for either outcomes (all P>0·2). 
 
Results for Mendelian randomization analyses 
Genetically-predicted concentration/activity of IL-6 and CRP were associated with both 
depression and anxiety. However, these associations differed with regards to direction of 
association (i.e., increased vs decreased risk), particular outcome definition, and sex. Table 4 
shows results for IVW MR analyses based on Georgakis et al.38 genetic instruments for CRP 
and IL-6.  
For CRP, per-unit increase in genetically-predicted concentrations of log-transformed CRP 
was associated with lower risk for depressive symptoms (1-sample MR: OR=0·89; 95% CI, 
0·79-1·00; 2-sample MR: OR=0·88; 95% CI, 0·80-0·98), and lower risk for anxiety 
symptoms (1-sample MR: OR=0·88; 95% CI, 0·79-0·97; 2-sample MR: OR=0·87; 95% CI, 
0·80-0·95). Using the categorical outcomes, MR analyses also showed that increased 
genetically-predicted CRP was associated with lower risk for probable GAD, but point 
estimates for probable depression were close to one (Table 4). In sex-stratified MR analyses, 
higher genetically predicted CRP concentrations were associated with relatively lower risk 





For IL-6, per-unit increase in higher genetically-predicted IL-6 activity was associated with 
increased risk for depressive symptoms (1-sample MR: OR=1·32, 95% CI 1·03-1·67; 2-
sample MR: OR=1·34, 95% CI 1·05-1·72), but not with probable depression or either anxiety 
outcome. In sex-stratified MR analyses, we found evidence that higher genetically-predicted 
IL-6 activity was associated with increased risk for depressive symptoms, probable 
depression, and probable GAD in women only. 
MR analyses using alternative genetic instruments were directionally consistent with these 
results, albeit with larger confidence intervals possibly due to the lower statistical power for 
these instruments (Supplementary Table 4). Results for sensitivity analyses evaluating the 
impact of selection/collider bias were similar to main IVW analyses (Supplementary Table 
5).  
Evidence did not suggest directional horizontal pleiotropy was a likely explanation for any of 





Based on data from the UK Biobank cohort, a large general population cohort, we report that 
circulating CRP concentrations are associated with depressive and anxiety symptoms and 
with probable diagnoses of depression and GAD in a linear, dose-response fashion. At the 
same time, we show evidence for disorder-specificity suggesting that CRP is more strongly 
associated with depression compared to anxiety. We also found some evidence for sex-
specificity. CRP was more strongly associated with depression in women than in men. Using 
MR analyses, we provide evidence that higher IL-6 activity could represent a potential causal 
factor increasing depression, while genetically predicted higher CRP concentrations appeared 
to potentially be protective for depression and anxiety, which contrasts findings for serum 
CRP.  
Although inflammation was associated with both depression and anxiety, we report stronger 
associations for depression outcomes indicating disorder-specificity. This aligns with meta-
analyses of case-control studies showing higher concentrations of CRP and other 
inflammatory markers in depression,3,4,6–8 while there are relatively fewer studies suggesting 
this for anxiety.13 Cohort studies of affective symptoms also suggest that circulating IL-6 and 
CRP concentrations are predominantly associated with depressive rather than anxiety 
symptoms.29 Together, current evidence is consistent with the idea that systemic 
inflammation may be particularly relevant for depression rather than anxiety disorders.  
Our results also provide some evidence for sex-specificity. Associations of serum CRP 
concentrations with depression and anxiety were mostly stronger in women than men. Results 
for sex-stratified MR analyses suggested that higher IL-6 could be a risk factor for depressive 
symptoms specifically for women while higher CRP could be protective for depressive 
symptoms specifically for men and for anxiety symptoms specifically for women. It is 
important to note, however, that confidence intervals of sex-stratified MR estimates 
overlapped between sexes emphasising the tentative nature of these results. Existing evidence 
on potential sex-difference for associations between inflammatory makers and depression has 
also been mixed. A previous meta-analysis reported no sex-specificity of the association 
between CRP and depression.3 In contrast, two recent studies reported that IL-6 was 
associated with depressive symptom chronicity and treatment response specifically in 
women.20,42 Atypical depression, which is characterised by immuno-metabolic dysregulation, 




considered sex as a covariate. Further research is needed to replicate our findings regarding 
potential sex-specificity. 
Our findings lend support to RCTs testing immunotherapies targeting the IL-6/IL-6R 
pathway for patients with depression. Anti-inflammatory treatments have been shown to 
exhibit antidepressant activity in chronic inflammatory illnesses.44–46 In depression, initial 
results suggest that these drugs may be useful for patients with evidence of inflammation and 
inflammation-related risk factors.47–49 This hypothesis is now being investigated in ongoing 
RCTs that are selecting patients based on evidence of inflammation and inflammation-related 
phenotypes.9,50 The present study further highlights characteristics associated with 
inflammation, e.g., female sex, to inform stratified patient selection in future clinical trials.  
 
Using genetic variants in the IL6R and CRP gene loci, we have found that higher genetically 
predicted IL-6 activity was associated with increased risk of depression, but higher 
genetically predicted CRP levels were associated with decreased risk of depression. These 
findings are intriguing because IL-6 signalling is a key driver of CRP response,51,52 and so we 
would expect both to affect depression risk in a comparable way. One potential explanation 
could be that IL-6 classic and trans-signalling have divergent effects on depression risk. We 
have illustrated this hypothesis in Figure 2, which describes IL-6 signalling pathways and a 
Directed Acyclic Graph of these pathways incorporating our MR results.  
In brief, IL-6 classic signalling occurs via its action on membrane-bound IL-6 receptors (IL-
6Rs) expressed by limited cell types. IL-6 also binds with circulating soluble IL-6R (sIL-6R) 
to form an IL-6-sIL-6R complex, which then activates IL-6 signalling by binding with the 
ubiquitous glycoprotein 130 on other cells that naturally lack IL-6Rs. This is called IL-6 
trans-signalling, which is thought to underlie pro-inflammatory effects of IL-6 in chronic 
inflammatory diseases.51  
Mechanistically, the observed increased depression risk conferred by IL6R SNPs that increase 
CRP levels38 could happen as a result of either increased IL-6 classic or trans-signalling. Our 
results indicate that it may be due to increased trans-signalling, because we also see that 
SNPs in the CRP gene that increase CRP levels38 are protective for depression. It is well-
known that CRP is mainly produced by hepatocytes as a result of increased IL-6 classic 
signalling.51 Taken together, these findings also align with a recent MR study on the effects 




recurrent depression, which suggested that increased IL-6 trans-signalling or decreased IL-6 
classic signalling could be responsible for a risk-increase in recurrent depressive symptoms.28  
While our findings suggest that altered activity of the IL-6/IL-6R pathway could be a risk 
factor for depression, disentangling the issue of IL-6 classic vs trans-signalling is beyond the 
scope of population genomics approaches as full effects of genetic variants used are 
unknown. The field now requires experimental studies of IL-6 modulation in humans and 
animals to further examine causality, pathogenic mechanisms, and therapeutic potential of 
anti-IL-6 and other immunotherapies for depression. Findings from these studies may help to 
devise more targeted IL-6 pathway-specific interventions. 
 
Strengths of the work include use of a large population-based sample, a range of affective 
symptoms, and complementary analysis using protein levels and genetic variants. We 
assessed reproducibility and strength of association using different outcomes and sex-
stratified analysis, evidence of linearity and potential causality of associations. Limitations of 
the work include focus on self-reported symptom score/probable diagnosis. Self-report 
measures of depression can capture different characteristics than observer-rated measures, so 
findings need to be replicated using the observer-rated modality.53 Depression is also a 
phenotypically heterogeneous syndrome and previous studies have reported that 
inflammation may be associated with specific symptoms, such as fatigue, changes in appetite 
and sleep, and suicidality.27,29,43 Aetiology of depressive symptoms could also vary across the 
lifespan, so findings from UK Biobank participants (mean age of 57 years) need to be 
replicated in other age groups. Second, although there was little evidence that associations of 
CRP with depression and anxiety could be due to selection/collider bias into the optional UK 
Biobank Mental Health Survey, selection/collider bias for participation in the UK Biobank 
cohort itself would likely be larger and remains a possible explanation for our findings that 
we could not explore. This is particularly relevant as the UK Biobank study includes 
individuals who are among others older, more likely to be women, healthier and of higher 
socioeconomic status compared to the general UK population.54 Third, MR findings were 
based on a subgroup of individuals of European ancestry, which is a common issue in genetic 
studies, warranting replication in other ethnic groups. Finally, IL-6 was not measured in the 
UK Biobank cohort, so we were unable to assess associations of serum IL-6 concentrations 




In conclusion, we report evidence for associations of higher serum CRP concentrations with 
depressive and anxiety symptoms, which are stronger for depressive than for anxiety 
symptoms and, although less consistently, for women than for men. Findings from MR 
analyses are consistent with a role of altered activity of the IL-6/IL-6R pathway in depressive 
symptoms, suggesting that this pathway could be a promising, new therapeutic target for 
depression. Due to uncertainties regarding the full functional effects of genetic variants used 
as MR instruments, the field now requires human and animal experimental studies to 
elucidate mechanisms for divergent effects for CRP and IL-6 on illness risk. This may help to 
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TABLES & FIGURES 
Table 1. Baseline characteristics of study participants by quintiles of CRP levels in the 
UK Biobank cohort (n=146,954) 








(n=24,196) P value 






3·33) 5·42 (3·34-78·22) <0·001 
Age (years) 54·3 (7·8) 55·82 (7·7) 56·5 (7·6) 56·9 (7·6) 56·6 (7·7) <0·001 
Women (%) 20262 (58·3) 17255 (53·7) 15588 (53·5) 14867 (55·6) 14931 (61·7) <0·001 
White ethnicity (%) 33601 (96·6) 31166 (97·0) 28228 (97·0) 25907 (96·9) 23399 (96·7) <0·001 
TDI, median (SD) -1·7 (2·8) -1·8 (2·8) -1·8 (2·8) -1·7 (2·8) -1·5 (2·9) <0·001 
BMI (kg/m2) 24·1 (3·1) 25·8 (3·4) 27·0 (3·9) 28·2 (4·3) 30·1 (5·8) <0·001 
Smoking status (%)       
    Never 21603 (62·1) 18927 (58·9) 16509 (56·7) 14722 (55·1) 12555 (51·9)  
    Current 1965 (5·7) 1981 (6·2) 2057 (7·1) 2162 (8·1) 2418 (10·0)  
    Ex-smokers 11157 (32·1) 11138 (34·7) 10484 (36·0) 9783 (36·6) 9163 (37·9) <0·001 
Alcohol status (%)       
    Never/Ex 1743 (5·0) 1581 (4·9) 1578 (5·4) 1633 (6·1) 1659 (6·9)  
    Occasional (≤ 3 times per week) 14376 (41·3) 13856 (43·2) 13052 (44·8) 12719 (47·6) 12184 (50·4)  
    Regular (> 3 times per week) 18657 (53·7) 16677 (51·9) 14475 (49·7) 12369 (46·3) 10342 (42·8) <0·001 
Physical activity (%)       
    Inactivity 27490 (90·0) 24961 (80·1) 22180 (79·1) 19756 (77·7) 16816 (74·9)  
    Moderately inactive 1350 (4·0) 1548 (5·0) 1633 (5·8) 1742 (6·9) 1969 (8·8)  
    Moderately active 4342 (12·8) 3881 (12·5) 3443 (12·3) 3206 (12·6) 2967 (13·2)  
    Active 779 (2·3) 778 (2·5) 780 (2·8) 722 (2·8) 711 (3·2) <0·001 
Diabetes (%) 780 (2·2) 881 (2·7) 983 (3·4) 1022 (3·8) 1210 (5·0) <0·001 
Cardiovascular disease (%) 1029 (3·0) 1093 (3·4) 1076 (3·7) 1035 (3·9) 973 (4·0) <0·001 
Note: Differences were estimated using mean and SD for continuous variables, with p-values from ANOVA 




Table 2. Association of C-reactive protein levels with probable diagnosis of depression in the UK Biobank cohort 













Per-Q effect P-value 
for trend 
All participants (cases = 8,888; controls = 145,468) 
Model 1 (n=144890) 1·27 (1·24-1·29) 1 [reference] 1·11 (1·03-1·19) 1·19 (1·10-1·28) 1·44 (1·34-1·54) 2·05 (1·91-2·20) 1·19 (1·17-1·21) <0·001 
Model 2 (n=144600) 1·12 (1·09-1·15) 1 [reference] 1·08 (1·00-1·16) 1·10 (1·02-1·18) 1·22 (1·13-1·31) 1·41 (1·31-1·53) 1·09 (1·07-1·10) <0·001 
Model 3 (n=138766) 1·09 (1·06-1·11) 1 [reference] 1·07 (0·99-1·15) 1·08 (1·00-1·17) 1·16 (1·07-1·26) 1·28 (1·18-1·39) 1·06 (1·04-1·08) <0·001 
Model 4 (n=138765) 1·09 (1·06-1·11) 1 [reference] 1·07 (0·99-1·16) 1·08 (1·00-1·17) 1·16 (1·07-1·26) 1·29 (1·18-1·40) 1·06 (1·04-1·08) <0·001 
Women (cases = 5,641; controls = 81,562) 
Model 1 (n=81610) 1·28 (1·25-1·32) 1 [reference] 1·06 (0·96-1·16) 1·22 (1·12-1·34) 1·40 (1·28-1·53) 2·11 (1·94-2·29) 1·20 (1·18-1·23) <0·001 
Model 2 (n=81454) 1·12 (1·08-1·15) 1 [reference] 1·03 (0·94-1·13) 1·13 (1·03-1·24) 1·18 (1·07-1·30) 1·41 (1·27-1·55) 1·09 (1·06-1·11) <0·001 
Model 3 (n=77818) 1·10 (1·06-1·14) 1 [reference] 1·02 (0·93-1·13) 1·13 (1·02-1·25) 1·17 (1·06-1·30) 1·33 (1·20-1·48) 1·07 (1·05-1·10) <0·001 
Model 4 (n=77818) 1·10 (1·06-1·13) 1 [reference] 1·02 (0·93-1·13) 1·13 (1·02-1·25) 1·17 (1·06-1·30) 1·33 (1·20-1·48) 1·07 (1·05-1·10) <0·001 
Men (cases = 3,247; controls = 63,906) 
Model 1 (n=63280) 1·22 (1·18-1·27) 1 [reference] 1·23 (1·09-1·38) 1·17 (1·04-1·32) 1·53 (1·36-1·72) 1·87 (1·66-2·11) 1·16 (1·13-1·19) <0·001 
Model 2 (n=63146) 1·13(1·08-1·17) 1 [reference] 1·16 (1·03-1·30) 1·04 (0·92-1·18) 1·27 (1·12-1·43) 1·44 (1·27-1·64) 1·08 (1·05-1·12) <0·001 
Model 3 (n=60948) 1·07 (1·02-1·11) 1 [reference] 1·12 (0·99-1·27) 1·00 (0·88-1·14) 1·14 (1·00-1·29) 1·21 (1·06-1·39) 1·04 (1·01-1·07) 0·02 
Model 4 (n=60947) 1·07 (1·03-1·12) 1 [reference] 1·13 (1·00-1·28) 1·01 (0·89-1·15) 1·15 (1·01-1·31) 1·23 (1·07-1·41) 1·04 (1·01-1·07) 0·01 
Data show OR and 95% CIs unless otherwise indicated. P for trend is from regression models with quintiles. Model 1, unadjusted; model 2, adjusted for age, sex, and BMI 
(body mass index); model 3, model 2 additionally adjusted for smoking, alcohol, physical activity, ethnicity, and TDI (Townsend deprivation index at recruitment); model 4, 





Table 3. Association of C-reactive protein levels with probable GAD diagnosis in the UK Biobank cohort 













Per-Q effect P for 
trend 
All participants (cases = 6,395; controls = 139,143) 
Model 1 (n=145,538) 1·11 (1·08-1·14) 1 [reference] 0·95 (0·88-1·03) 0·95 (0·88-1·03) 1·05 (0·97-1·13) 1·38 (1·28-1·49) 1·08 (1·06-1·10) <0·001 
Model 2 (n=145,239) 1·07 (1·04-1·10) 1 [reference] 0·99 (0·91-1·07) 0·99 (0·91-1·07) 1·05 (0·97-1·14) 1·24 (1·14-1·36) 1·05 (1·03-1·07) <0·001 
Model 3 (n=139,341) 1·05 (1·02-1·08) 1 [reference] 0·97 (0·90-1·06) 0·99 (0·91-1·07) 1·02 (0·94-1·12) 1·15 (1·05-1·26) 1·03 (1·01-1·05) 0·004 
Model 4 (n=139,340) 1·05 (1·02-1·08) 1 [reference] 0·98 (0·90-1·06) 0·98 (0·90-1·07) 1·02 (0·94-1·11) 1·15 (1·05-1·26) 1·03 (1·01-1·05) 0·005 
Women (cases = 4,247; controls = 77,717) 
Model 1 (n=81,964) 1·10 (1·07-1·13) 1 [reference] 0·97 (0·88-1·07) 0·95 (0·86-1·05) 1·03 (0·93-1·13) 1·38 (1·26-1·51) 1·07 (1·05-1·10) <0·001 
Model 2 (n=81,799) 1·08 (1·04-1·11) 1 [reference] 1·00 (0·91-1·10) 0·98 (0·88-1·08) 1·05 (0·94-1·16) 1·29 (1·16-1·43) 1·05 (1·03-1·08) <0·001 
Model 3 (n=78,110) 1·07 (1·03-1·10) 1 [reference] 0·98 (0·89-1·09) 0·99 (0·90-1·10) 1·04 (0·94-1·16) 1·23 (1·10-1·38) 1·05 (1·02-1·07) 0·001 
Model 4 (n=78,110) 1·06 (1·03-1·10) 1 [reference] 0·99 (0·89-1·09) 0·99 (0·89-1·10) 1·04 (0·93-1·16) 1·23 (1·10-1·37) 1·05 (1·02-1·07) 0·001 
Men (cases = 2,148; controls = 61,426) 
Model 1 (n=63,574) 1·10 (1·06-1·16) 1 [reference] 0·97 (0·85-1·11) 1·02 (0·89-1·17) 1·12 (0·98-1·28) 1·33 (1·16-1·53) 1·07 (1·04-1·11) <0·001 
Model 2 (n=63,440) 1·07 (1·02-1·12) 1 [reference] 0·97 (0·85-1·11) 1·02 (0·89-1·17) 1·12 (0·98-1·28) 1·33 (1·16-1·53) 1·04 (1·01-1·08) 0·018 
Model 3 (n=61,231) 1·02 (0·98-1·07) 1 [reference] 0·94 (0·82-1·08) 0·95 (0·83-1·10) 0·97 (0·84-1·13) 1·02 (0·87-1·20) 1·01 (0·97-1·04) 0·74 
Model 4 (n=61,230) 1·02 (0·98-1·07) 1 [reference] 0·95 (0·82-1·08) 0·95 (0·83-1·10) 0·97 (0·84-1·13) 1·02 (0·87-1·20) 1·01 (0·97-1·04) 0·74 
Note: Data show ORs and 95% CIs unless otherwise indicated. P for trend is from regression models with quintiles. Model 1, unadjusted; model 2, adjusted for age, sex, and 
BMI (body mass index); model 3, model 2 additionally adjusted for smoking, alcohol, physical activity, ethnicity, and TDI (Townsend deprivation index at recruitment); 






Table 4. IVW Mendelian randomisation analysis of association of IL-6 and CRP with depression and anxiety 
 Depression Symptom Score Probable depression Anxiety Symptom Score Probable GAD 
Model OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
CRP         
2-Sample MR 0·88 (0·80-0·98) 0·020 0·95 (0·85-1·07) 0·424 0·87 (0·80-0·95) 0·003 0·82 (0·72-0·94) 0·004 
1-Sample MR 0·89 (0·79-1·00) 0·055 1·01 (0·88-1·14) 0·939 0·88 (0·79-0·97) 0·008 0·84 (0·73-0·98) 0·027 
   Women 0·98 (0·85-1·12) 0·754 1·12 (0·96-1·30) 0·152 0·86 (0·76-0·98) 0·023 0·85 (0·72-1·01) 0·059 
   Men 0·78 (0·63-0·96) 0·018 0·84 (0·66-1·06) 0·138 0·91 (0·78-1·05) 0·192 0·83 (0·62-1·11) 0·209 
IL-6         
2-Sample MR 1·34 (1·05-1·72) 0·019 1·15 (0·86-1·54) 0·340 1·13 (0·91-1·41) 0·269 1·24 (0·89-1·73) 0·194 
1-Sample MR 1·32 (1·03-1·67) 0·025 1·18 (0·89-1·56) 0·246 1·11 (0·90-1·37) 0·313 1·18 (0·86-1·62) 0·297 
   Women 1·42 (1·01-1·97) 0·041 1·46 (1·00-2·13) 0·048 1·15 (0·85-1·56) 0·362 1·51 (1·01-2·25) 0·044 
   Men 1·24 (0·88-1·74) 0·218 0·86 (0·54-1·37) 0·516 1·08 (0·79-1·47) 0·636 0·79 (0·47-1·33) 0·385 




Figure 1. Odds ratios for higher depressive and anxiety symptom scores per decile of 















Error bars represent 95% confidence intervals (CIs), which were calculated using a floating absolute risk 
technique; CRP: C-reactive protein; Odds ratios were adjusted for age, sex, BMI, smoking status, alcohol intake, 
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Figure 2. Potential divergent effects of specific IL-6 signalling pathways on depression 
risk 
 
Note: Figure 2A shows IL-6 classic and trans-signalling pathways; see review by Hunter and Jones 51. Figure 2B 
displays our working hypothesis arising from MR results that IL-6 trans-signalling confers increased risk for 
depression. 1MR estimates are based on 2-sample MR analysis using Georgakis et al. 38 genetic instruments and 
continuous depressive symptoms as outcome (cf. Table 4). Abbreviations: gp130=glycoprotein 130; 
Dep.=depression; CRP=C-reactive protein; IL-6=interleukin-6. 
 
 
 
